Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Drug: PEG-L-asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: etoposideDrug: mercaptopurineDrug: ifosfamideDrug: methotrexateDrug: vincristine sulfateDrug: prednisoneRadiation: Radiation TherapyDrug: thioguanineDrug: vindesineDrug: daunoxomeDrug: fludarabine
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 6136
- Registration Number
- NCT01117441
- Locations
- 🇦🇹
A.oe. Landeskrankenhaus Klagenfurt, Abt. für Kinder- und Jugendheilkunde, Klagenfurt, Austria
🇨🇿University Hospital Brno, Department of Pediatric Oncology, Brno, Czechia
🇩🇪Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie, Berlin, Germany
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
- Conditions
- Leukemia, Myelogenous, Acute
- Interventions
- Biological: Natural Killer CellsDrug: FludarabineDrug: CyclophosphamideDrug: Denileukin diftitoxProcedure: Donor lymphapheresisDrug: IL-2
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT01106950
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia
- Conditions
- Aplastic Anemia
- Interventions
- Biological: anti-thymocyte globulinBiological: filgrastimDrug: FludarabineDrug: CyclophosphamideProcedure: CD3±CD19 depleted hematopoietic stem cell transplantation
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT01105273
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerBreast CancerPrimary Peritoneal Cancer
- Interventions
- Drug: FludarabineDrug: CyclophosphamideDrug: CyclosporineBiological: Natural killer cellsDrug: IL-2Drug: Interleukin-2Drug: Methylprednisolone
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 13
- Registration Number
- NCT01105650
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT01096992
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic LeukemiaIndolent Non-Hodgkin's LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 241
- Registration Number
- NCT01088048
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- LeukemiaOral ComplicationsMucositis
- Interventions
- Biological: rituximabBiological: paliferminDrug: cyclophosphamideProcedure: allogeneic hematopoietic stem cell transplantationDrug: cytarabineDrug: daunorubicin hydrochlorideRadiation: total-body irradiationDrug: etoposideDrug: fludarabine phosphateDrug: imatinib mesylateDrug: melphalanDrug: mercaptopurineDrug: methotrexateDrug: nelarabineDrug: pegaspargaseDrug: vincristine sulfate
- First Posted Date
- 2010-03-12
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University College, London
- Target Recruit Count
- 1033
- Registration Number
- NCT01085617
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2010-03-09
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT01082939
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Hematopoietic Stem Cell Transplant for Fanconi Anemia
- Conditions
- Fanconi Anemia
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 1
- Registration Number
- NCT01071239
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
- Conditions
- Adult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Blastic Phase Chronic Myelogenous Leukemiade Novo Myelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesChildhood Acute Myeloid Leukemia in RemissionChildhood Myelodysplastic SyndromesRecurrent Adult Acute Myeloid Leukemia
- Interventions
- Drug: fludarabine phosphateDrug: busulfanBiological: anti-thymocyte globulinDrug: tacrolimusDrug: methotrexateProcedure: peripheral blood stem cell transplantationProcedure: allogeneic hematopoietic stem cell transplantationOther: laboratory biomarker analysis
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT01056614
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.